Gray Heidi Dept web

Heidi J Gray, MD

Associate Professor

 
Joined UW Medicine:

7/16/04

Clinical Focus:

Gynecologic Oncology:
• Complex gynecologic oncology surgery
• Treatment of gynecologic cancers
• Clinical trials for gynecologic cancers
• Immunotherapy for gynecologic malignancies
• Robotic surgery

Licensure:

Washington, 1999

Certification:

• Obstetrics and Gynecology, 2005
• Gynecologic Oncology, 2007

Education:

• MD Degree
   (University of California, Los Angeles, 1997)
• Residency in Obstetrics and Gynecology
   (University of Washington, 2001)
• Fellowship in Gynecologic Oncology
   (Hospital of University of Pennsylvania, 2004)

Research Interests:

• Immunotherapy for gynecologic malignancies
• Clinical trials

Current Research:

Identification of an Immunologic Signature of Ovarian Cancer
for Use as an Early Cancer Screen

Memberships:

• American Congress of Obstetricians and Gynecologists
• Gynecologic Oncology Group
• Puget Sound Oncology Consortium
• Society of Gynecologic Oncologists
• Western Association of Gynecologic Oncologists

Selected Publications:

Thrall MM, Gray HJ, Symons RG, Weiss NS, Flum DR, Goff BA. Trends in treatment of advanced epithelial ovarian cancer in the Medicare population. Gynecol Oncol 2011 Jul;122(1):100-6.

Press JZ, Allison KH, Garcia R, Everett EN, Pizer E, Swensen RE, Tamimi HK, Gray HJ, Goff BA. FOXP3+ regulatory T-cells are abundant in vulvar Paget's disease and are associated with recurrence. Gynecol Oncol 2011 Feb;120(2):296-9.

Thrall MM, Goff BA, Symons RG, Flum DR, Gray HJ. Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. Obstet Gynecol 2011 Sep;118(3):537-47.

McLean KA, Zhang W, Dunsmoor-Su RF, Shah CA, Gray HJ, Swensen RE, Goff BA. Pelvic exenteration in the age of modern chemoradiation. Gynecol Oncol 2011 Apr;121(1):131-4.

Gray HJ. Advances in vulvar and vaginal cancer treatment. Gynecol Oncol 2010 Jul;118(1):3-5.

McLean KA, Shah CA, Thompson SA, Gray HJ, Swensen RE, Goff BA. Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction. Gynecol Oncol 2010 Jul;118(1):43-6.

Gray HJ, Seifert E, Sal y Rosas VG, Nicandri KF, Koh WJ, Goff BA. The abandoned radical hysterectomy for cervical cancer: clinical predictors and outcomes. Obstet Gynecol Int 2010;2010;743794

Gray HJ, Shah CA, Swensen RE, Tamimi HK, Goff BA. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer. Gynecol Oncol 2010 Mar;116(3):340-4.

Shah CA, Allison KH, Garcia RL, Gray HJ, Goff BA, Swisher EM. Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol Oncol 2008 May;109(2):215-9.

Gray HJ. Primary management of early stage cervical cancer (IA1-IB) and appropriate selection of adjuvant therapy. J Natl Comp Canc Netw 2008 Jan;6(1):47-52.

Fox KV, Shah CA, Swisher EM, Garcia RL, Mandel LS, Gray HJ, Swensen RE, Goff BA. An evaluation of cervical cancer in women age sixty and over. Gynecol Oncol 2008 Apr;109(1):53-8.

Galic V, Willner J, Wollan M, Garg R, Garcia R, Goff BA, Gray HJ, Swisher EM Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes, Chromosomes Cancer 2007 Mar;46(3):239-47.

Garg R, Wollan M, Galic V, Garcia R, Goff BA, Gray HJ, Swisher E. Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma. Gynecol Oncol 2006 Dec;103(3):793-6.

Greer BE, Swensen RE, Gray HJ. Surgery for ovarian cancer: rationale and guidelines. J Natl Comp Canc Netw 2004 Nov;2(6):561-8.

Gray HJ, Garcia R, Tamimi HK, Koh WJ, Goff BA, Greer BE, Paley PJ. Glassy cell carcinoma of the cervix revisited. Gynecol Oncol 2002 May;85(2):274-7.

Appointments & Practice Locations

Seattle Cancer Care Alliance (SCCA)
1354 Aloha Street, Seattle, WA 98109

Appointments:   206.288.7155 (new patients)
                           206.288.6200 (return pts)